This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

2016 End-of-Year Summary of FDA Advertising and Promotion Enforcement Activity

January 9, 2017, Covington Alert

This alert reviews trends emerging from the warning and untitled letters issued in 2016 by the Office of Prescription Drug Promotion (OPDP) of the Center for Drug Evaluation and Research (CDER). No warning or untitled letters concerning promotion were issued this year by the Office of Compliance and Biologics Quality (OCBQ) of the Center for Biologics Evaluation and Research (CBER) or by the Office of Compliance (OC) of the Center for Devices and Radiological Health (CDRH).

Share this article: